Condition: Biliary Tract Neoplasms Immunotherapy · Sponsor: Peking Union Medical College Hospital
An investigation into the survival outcomes, progression-free survival, and safety of triple therapy with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib in patients with advanced HER2-positive/low-expressing biliary tract cancer after the failure of at least two prior systemic therapies.
This description comes directly from the study's public registry record.
Shuman Kuang · +86-10-69156042 · kuangshuman@163.com
Always discuss trial participation with your own doctor first.
| Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH) | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07704177